LINC00665: A Promising Biomarker in Gastrointestinal Tumors

Curr Mol Med. 2024;24(1):51-59. doi: 10.2174/1566524023666221201141443.

Abstract

An increasing volume of studies has reported that long non-codingRNAs (lncRNAs) are involved in the carcinogenesis of many different cancers. Especially in gastrointestinal tumors, lncRNAs are found to participate in various physiological and pathological processes. LncRNAs can regulate gene expression at multiple levels, including transcriptional, post-transcription, translational, and post-translational levels. Long intergenic non-protein coding RNA 665(LINC00665), a novel cancer-related lncRNA, is frequently dysregulated in multiple gastrointestinal tumors, including gastric and colorectal cancers, hepatocellular carcinoma, and so on. In this review, we analyzed the expression and prognostic value of LINC00665 in human gastrointestinal tumors, systematically summarized the current literature about the clinical significance of this lncRNA, and explored the regulatory mechanisms of LINC00665 as a competing endogenous RNA (ceRNA) in tumor progression. Consequently, we concluded that LINC00665 might act as a prognostic biomarker and a potential target for gastrointestinal tumor diagnosis and treatment.

Keywords: CeRNA.; LINC00665; biomarker; diagnosis; gastrointestinal tumors; prognosis; therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Carcinoma, Hepatocellular* / genetics
  • Gastrointestinal Neoplasms* / diagnosis
  • Gastrointestinal Neoplasms* / genetics
  • Humans
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / pathology
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding
  • Biomarkers, Tumor